Skip to main content
Marksans Pharma Ltd. logo

Marksans Pharma Ltd. — Investor Relations & Filings

Ticker · MARKSANS ISIN · INE750C01026 LEI · 335800YXQPMPSAC51K30 BSE.NS Manufacturing
Open in API
Filings indexed 738 across all filing types
Latest filing 2026-05-26 Regulatory Filings
Country IN India
Listing BSE.NS MARKSANS

About Marksans Pharma Ltd.

https://www.marksanspharma.com

Marksans Pharma Ltd. specializes in the research, development, and large-scale manufacturing of generic formulations. The company’s therapeutic focus spans pain management, cardiovascular health, central nervous system disorders, anti-diabetics, and gastrointestinal treatments. Its product portfolio includes diverse delivery systems such as solid orals, soft gelatin capsules, and liquid formulations, serving both the over-the-counter and prescription markets. The organization operates advanced manufacturing facilities compliant with international regulatory standards, facilitating a robust supply chain across major global markets including North America, Europe, and Australia. By integrating comprehensive research and development with efficient production processes, the company provides a broad range of high-quality, cost-effective medicinal products to a global patient base.

Recent filings

Filing Released Lang Actions
The Board has recommended Dividend of Rs. 0.90 per share subject to approval of Shareholders at ensuing Annual General Meeting
Regulatory Filings Classification · 85% confidence The document is a formal announcement to the stock exchanges under SEBI Listing Regulations (Regulation 33/30) of Marksans Pharma’s audited financial results for the quarter and full year ended March 31, 2026, including the Independent Auditor’s Report. It is not a full Annual Report (10-K) nor a shortened earnings release (ER), nor an interim/quarterly report (IR) because it covers the full fiscal year and includes detailed audited results and audit opinion. It is also not merely a publication notice (RPA) but the actual regulatory filing of audited financial results. Therefore, it best fits into the general Regulatory Filings category (RNS).
2026-05-26 English
Press Release
Earnings Release Classification · 88% confidence The document is a press release announcing the audited financial results for Q4 and the full fiscal year ended March 31, 2026, with key financial highlights, tables of P&L figures, and an earnings conference call notice. It does not constitute the full Annual Report (10-K) or a comprehensive interim report, but is the initial public announcement of periodical results, matching the definition of an Earnings Release (ER). FY 2026
2026-05-26 English
Marksans Pharma Limited Press Release on Q4 FY26 Results
Earnings Release Classification · 93% confidence The document is a press release titled “Q4 & FY26 Financial Results” summarizing audited standalone and consolidated results for the quarter and full year ended March 31, 2026. It provides key financial highlights (revenue, EBITDA, PAT, EPS), segment performance, consolidated P&L tables, and an earnings conference call announcement. This is an initial announcement of periodical financial results, which matches the definition of an Earnings Release. FY 2026
2026-05-26 English
Investor Presentation
Investor Presentation Classification · 98% confidence The document is clearly formatted as an investor presentation for Q4FY26 and FY26, containing extensive slides on financial and business highlights, strategic initiatives, market breakdowns, management commentary, and product launch tables. It is addressed to BSE and NSE under SEBI Listing Regulations as “Investor Presentation,” and contains substantive content rather than merely announcing or certifying a report. This matches the definition of an Investor Presentation (Code: IP).
2026-05-26 English
Investors Presentation Q4 FY26
Investor Presentation Classification · 96% confidence The document is a slide presentation titled “Investor Presentation” for Q4 FY26, filed pursuant to SEBI LODR Regulation 30. It contains detailed business and financial highlights, segment and geographic analysis, strategic initiatives, and outlook. It is not a statutory annual or interim report, earnings press release, or regulatory notice, but a comprehensive investor slide deck. This matches the definition of an Investor Presentation (Code: IP).
2026-05-26 English
Dividend
Audit Report / Information Classification · 92% confidence The document is a regulatory announcement under SEBI Listing Regulations that encloses the Audited Financial Results (Stand-alone and Consolidated) for the year ended March 31, 2026 along with the Statutory Auditor’s Independent Auditor’s Report. It is not a full annual report (10-K) nor merely a brief earnings release; rather, it is a standalone audit report with accompanying financial statements. Therefore it best fits the “Audit Report / Information” category. FY 2026
2026-05-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.